Last reviewed · How we verify
NCT04367142: COR-DIAL-1
Rapid Detection of COVID-19 by Portable and Connected Biosensor
trial testing COVID-19 RT-PCR in Sars-CoV2 in 200 participants. Completed in 2 May 2023.
2 May 2023
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 24 August 2020 |
| Primary completion | 2 May 2023 |
| Estimated completion | 2 May 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- COVID-19 RT-PCR
- Biosensor
Conditions studied
- Sars-CoV2 — all drugs for Sars-CoV2 →
Sponsor
University Hospital, Lille
Who can join
Eligibility, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics.
Parihar A, Ranjan P, Sanghi SK, Srivastava AK, et al · · 2020 · cited 90× · PMID 35019474 · DOI 10.1021/acsabm.0c01083
Verify or expand the search:
- PubMed search for NCT04367142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19 RT-PCR
Trials testing the same drug.
- NCT04780334 — Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept · completed
- NCT04348422 — Evaluating the Immune Response for COVID-19 · completed
- NCT04368338 — Lung Ultrasound to Diagnose COVID-19 · completed
Other recruiting trials for Sars-CoV2
Currently open trials in the same condition.
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
- NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04367142 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 17 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04367142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing